Key result
Prolonged Impella support reduces cardiac immune cells and integrin expression in fulminant myocarditis.
Why the study?
Haemodynamic load induces cardiac remodelling and inflammatory responses, prompting the hypothesis that myocarditis requires a strategy that provides circulatory support while unloading the left ventricle and mitigating inflammation.
Does prolonged Impella support (PROPELLA concept) alter cardiac immune cell presence and integrin expression in fulminant myocarditis?
Does prolonged Impella support (PROPELLA concept) alter cardiac immune cell presence and integrin expression in fulminant myocarditis?
Prolonged Impella support in fulminant myocarditis may provide disease-altering effects by reducing cardiac inflammation and integrin expression, potentially enhancing myocardial recovery.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Like with ECMO, the Impella device also provides circulatory support, but the heart is unloaded. The Impella, which is implanted in the left ventricle, acts like a propeller in a boat. It swaps the blood out, so the heart does not have to pump. This reduces the volume load, and therefore reduces the stress for the heart.”
May support exploring Impella unloading in myocarditis; leaves open clinical benefit without randomized trials.
Spillmann et al. (2019) studied Fulminant myocarditis. Prolonged Impella support (PROPELLA concept) was evaluated on Cardiac immune cell presence and integrin expression. Prolonged Impella support (PROPELLA concept) in fulminant myocarditis decreased cardiac immune cell presence and integrin expression during left ventricular unloading.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: